Century Therapeutics to Present at the ASGCT 25th Annual Meeting

Rhea-AI Summary

Century Therapeutics (NASDAQ: IPSC) announced that preclinical data on MAD7, a novel CRISPR nuclease enabling genetic engineering of iPSC-derived NK and T cell therapies, will be presented at the ASGCT 25th Annual Meeting from May 16-19, 2022, in Washington, D.C. The presentation will focus on enhancing iPSC-based cell therapies, with details including an abstract number of 952, scheduled for May 18, 2022, at 5:30 PM ET. The company aims to overcome limitations of first-generation cell therapies with its innovative approaches to cancer treatment.

PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data on MAD7, a novel CRISPR nuclease used to enable the genetic engineering of iPSC-derived NK and T cell product candidates, will be presented in a poster at the American Society of Gene and Cell Therapy (ASGCT) 25^th Annual Meeting, on May 16-19, 2022 in Washington, D.C.

Details of the poster presentations are as follows:

Abstract Number: 952
Title: Enabling the Engineering of iPSC Based Cell Therapies Using MAD7, a Novel CRISPR Nuclease
Poster Board Number: W-78
Session Title: Gene Targeting and Gene Correction III
Session Date: Wednesday, May 18, 2022
Session Time: 5:30 PM - 6:30 PM ET
Room: Hall D
Presenter: Michael Naso, PhD, Vice President, Cell Engineering, Century Therapeutics

Full abstracts are currently available through the ASGCT conference website.

About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. For more information on Century Therapeutics please visit www.centurytx.com.

Century Therapeutics Forward-Looking Statement
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are not guarantees of future performance These risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

For More Information:
Company: Elizabeth Krutoholow – investor.relations@centurytx.com 
Investors: Melissa Forst/Maghan Meyers – century@argotpartners.com 
Media: Joshua R. Mansbach – century@argotpartners.com 

FAQ

What is the significance of Century Therapeutics' presentation at the ASGCT 2022?

Century Therapeutics will present crucial preclinical data on MAD7, a new CRISPR nuclease that facilitates genetic engineering of iPSC-derived NK and T cell therapies, highlighting advancements in cancer treatment.

When and where will the poster presentation on MAD7 take place?

The poster presentation will be held on May 18, 2022, during the ASGCT 25th Annual Meeting in Washington, D.C.

Who is presenting the research on MAD7 at the ASGCT?

Michael Naso, PhD, Vice President of Cell Engineering at Century Therapeutics, will present the research on MAD7.

What are the details of the poster presentation by Century Therapeutics?

The poster presentation's abstract number is 952, titled 'Enabling the Engineering of iPSC Based Cell Therapies Using MAD7,' scheduled for session III on May 18, 2022.

How does Century Therapeutics' research aim to improve cancer therapies?

Century Therapeutics focuses on developing iPSC-derived therapies that target hematologic and solid tumors, aiming to enhance the effectiveness and accessibility of cancer treatment.